Accueil   Diary - News   All news ERYTECH CONFIRMS STRATEGIC FOCUS OF ERYASPASE ON SOLID TUMORS...

ERYTECH CONFIRMS STRATEGIC FOCUS OF ERYASPASE ON SOLID TUMORS…

 

... and ceases development in acute lymphoblastic leukemia.

 

ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications. The company also announced that it plans to cease its development program for eryaspase in acute lymphoblastic leukemia (ALL), including the withdrawal of its previously submitted MAA for eryaspase for the treatment of relapsed and refractory ALL.


Read the press release